|
| Trial | Line of treatment | Phase | No. of patients | Medication | Overall response | Median OS (mo) | Median PFS (mo) |
|
| Monoclonal antibodies |
|
| E5397 Burtness et al. [45] | First | III | 117 | Cisplatin versus cisplatin/cetuximab | 10% versus 26% ( 0.03) | 8 versus 9.2 ( 0.21) | 2.7 versus 4.2 ( 0.09) |
| Vermorken et al. [39] | Second (platinum refractory) | II | 103 | Cetuximab | 13% | 6 | |
| EXTREME Vermorken and Specenier [51] | First | III | 442 | Platinum-based versus platin + cetuximab | 20% versus 36% () | 7.4 versus 10.1 ( 0.04) | 3.3 versus 5.6 () |
| SPECTRUM Vermorken et al. [49] | First | III | 657 | Cis/5FU versus Cis/5FU + panitumumab | 25% versus 36% | 9 versus 11.1 ( 0.14) | 4.6 versus 5.8 ( 0.004) |
| Zalute Machiels et al. [52] | Second after platinum | III | 286 | Zalutumumab versus support or methotrexate | 1.1 and versus 1.1% | 6.7 versus 5.2 ( 0.065) | 9.9 versus 8.4 ( 0.001) |
| Herbst et al. [42] | Second | II | 132 | Cis/cetuximab after progression on cis | 26% | 6.1 and 4.3 | |
| Hitt et al. [40] | Second | II | 46 | Paclitaxel + cetuximab | 60% | | 5.6 |
| Baselga et al. [44] | Second | II | 96 | Cetuximab + platinum | 10% | 6.1 | 2.8 |
|
| Tyrosine kinase inhibitors |
|
| IMEX Stewart et al. [53] | Second after platinum/no platinum | III | 486 | Gefitinib 250 versus gefitinib 500 versus methotrexate | 2.7% versus 7.6% versus 3.9% | 5.6 versus 6 versus 6.7 | |
| E1302 Argiris et al. [54] | Any | III | 270 | Docetaxel versus docetaxel + gefitinib 250 | 6% versus 12% ( 0.21) | 6.18 versus 6.83 ( 0.97) | 2.2 versus 3.35 ( 0.18) |
| BIBW2992 Seiwert et al. [55] | After platinum | III | 124 | Afatinib versus cetuximab | 22% versus 13% | | 3.75 versus 2.35 |
|
Siu et al. [56] | First | I/II | 51 | Erlotinib + cis | 21% | 7.9 | 3.3 |
| Cohen et al. [57] | Second | I/II | 48 | Erlotinib + bevacizumab | 14.5% | 7.1 | 4.1 |
| Cohen et al. [58] | First and second | II | 52 | Gefitinib | 10.6% | 8.1 | 3.4 |
|
